Potential side effects and safety assessment of daprodustat

Daprodustat (Daprodustat) promotes erythropoiesis through HIF-PH inhibition mechanism, but its safety still needs attention. Common side effects include increased blood pressure, dizziness, fatigue, edema, and mild to moderate blood level fluctuations. Some patients may have iron metabolism abnormalities, such as changes in serum iron, ferritin or transferrin saturation, which need to be managed in conjunction with an iron supplementation program.

Multicenter clinical studies have shown that daplestat is generally well tolerated, but special attention needs to be paid to cardiovascular risks, such as heart failure, thrombosis, and abnormal heart rhythms, especially in patients with pre-existing cardiovascular disease. In order to reduce risks, clinical practice usually involves gradually adjusting the hemoglobin target value and regularly monitoring blood pressure, hemoglobin and blood test indicators. Abnormal liver function and further decline in renal function also require follow-up to ensure long-term safety.

Patient education is an important part of safety management. Patients need to be aware of possible symptoms, such as dizziness, palpitations, abnormal bleeding or fatigue, and report them to their doctor in a timely manner. Lifestyle management is also very important, including regular physical examinations, maintaining a reasonable diet and exercise, and controlling blood pressure and blood lipids. For dialysis patients, medication needs to be adjusted in conjunction with the dialysis regimen to reduce the risk of complications.

Overall, daporostat is highly safe. Through standardized use, close monitoring and timely treatment of adverse reactions, patients can effectively improve anemia while achieving long-term safe medication. Most of its side effects are controllable, and the risk of elevated blood pressure and cardiovascular events can be reduced through individualized dose adjustment and regular follow-up. Combining clinical guidelines and patient management experience, dapoprimostat provides a long-term, sustainable and safe treatment option for anemia of chronic kidney disease, while taking into account life convenience and compliance, bringing overall improvement to patients.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat

xa0